The Effects of Losartan on Reward Reinforcement Learning
2020年10月21日 更新者:Benjamin Becker、University of Electronic Science and Technology of China
The Role of the Renin-angiotensin System in Reward Reinforcement Learning
This study aims to investigate whether a single dose of losartan (50 mg) can affect learning from positive and negative outcomes and its related neural mechanisms.
研究概览
详细说明
Emerging evidence suggests that the renin-angiotensin system can impact dopamine (DA) transmission and its modulatory role in reward processing.
For instance, recent animal models have found that the angiotensin antagonist losartan reduces rewarding effects of methamphetamine and nicotine by modulating DA release in the striatum.The present study thus will investigate losartan effects on reward reinforcement learning and the underlying neural mechanisms.
In a double-blind, between-subject, placebo-controlled design, 60 healthy male subjects will be randomly assigned to receive single-dose losartan (50 mg) or placebo, 90 minutes before performing a probabilistic reinforcement learning task during fMRI.
研究类型
介入性
注册 (预期的)
60
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Sichuan
-
Chengdu、Sichuan、中国、611731
- 招聘中
- University of Electronic Science and Technology of China
-
接触:
- Weihua Zhao, PhD
- 邮箱:zarazhao.uestc@outlook.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 30年 (成人)
接受健康志愿者
是的
有资格学习的性别
男性
描述
Inclusion Criteria:
- Healthy subjects without past or current psychiatric or neurological disorders
- Right-handedness
- Normal or corrected-normal version
Exclusion Criteria:
- History of head injury
- Medical or psychiatric illness
- Hypertension
- General cardio-vascular alteration or diseases
- Allergy against medications
- Visual or motor impairments
- Claustrophobia
- Drug addiction
- Nicotine dependence
- FMRI contradictions
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:氯沙坦组
药物:氯沙坦
|
administration of losartan (50 mg) (oral)
其他名称:
|
|
安慰剂比较:安慰剂组
药物:安慰剂口服片剂
|
administration of placebo (oral)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
BOLD-level activity as assessed by fMRI during the learning phase
大体时间:90 minutes to 110 minutes after treatment
|
During the paradigm subjects will learn the reward properties of stimuli via the presentation of trial-wise feedback.
The neural activation during the prediction of positive and negative outcome feedback will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions.
The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.
|
90 minutes to 110 minutes after treatment
|
|
BOLD-level activity as assessed by fMRI during the learning transfer phase
大体时间:111 minutes to 120 minutes after treatment
|
Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities.
The neural activation during correct responses will be assessed by functional magnetic resonance imaging (fMRI), particularly in prefrontal and subcortical regions.
The effects of treatment will be determined by comparing the losartan- and placebo-treated groups.
|
111 minutes to 120 minutes after treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Choice accuracy for the stimulus with the high reward probability during the learning phase
大体时间:90 minutes to 110 minutes after treatment
|
During the learning phase accuracies (in percent) for choosing the stimulus with the highest reward probability will be computed.
Effects of treatment on choice accuracy in the probabilistic learning task will be examined by comparing accuracies (percent) between the losartan- and placebo-treated group.
|
90 minutes to 110 minutes after treatment
|
|
Learning rate for positive and negative outcomes
大体时间:90 minutes to 110 minutes after treatment
|
The learning rate will be determined by performing computational modelling.
The learning rate index for positive and negative outcomes during the learning phase will be compared between the losartan- and placebo-treated group.
|
90 minutes to 110 minutes after treatment
|
|
Choice accuracy during the learning transfer phase
大体时间:111 minutes to 120 minutes after treatment
|
Following the initial learning phase subjects learning transfer will be examined by asking subjects to choose between stimuli with high versus low reward probabilities.
For the transfer phase the choice accuracy for selecting stimuli with the highest reward probability and avoiding stimuli with the lowest reward probability will be computed.
The effects of treatment will be determined by comparing the accuracy between the losartan- and placebo-treated groups.
|
111 minutes to 120 minutes after treatment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Benjamin Becker, PhD、University of Electronic Science and Technology of China
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2020年10月10日
初级完成 (预期的)
2021年12月31日
研究完成 (预期的)
2022年3月31日
研究注册日期
首次提交
2020年10月9日
首先提交符合 QC 标准的
2020年10月21日
首次发布 (实际的)
2020年10月27日
研究记录更新
最后更新发布 (实际的)
2020年10月27日
上次提交的符合 QC 标准的更新
2020年10月21日
最后验证
2020年10月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- UESTC-neuSCAN-75
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.